A Study of Single and Multiple Doses of HRS-6257 in Healthy Subjects
Status:
NOT_YET_RECRUITING
Trial end date:
2026-05-01
Target enrollment:
Participant gender:
Summary
This is a phase I, randomised, single-blind placebo-controlled, 2-part study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics and food effect of single and multiple oral doses of HRS-6257 in healthy volunteers.